On May 21, ImmunityBio fell 7.89% in regular trading, trading at $7.345/share, with trading volume of $54.27 million. The decline comes as the stock experiences a pullback following a concentrated release of fundamental catalysts over recent days.

From May 17 through May 19, ImmunityBio announced a series of significant developments: an exclusive US agreement with Japan BCG Laboratory to develop, import, and commercialize intravesical Tokyo-172 BCG — a product backed by Phase 3 data demonstrating non-inferiority to TICE BCG; five US patents covering its ANKTIVA plus BCG combination therapy for cancer treatment with validity until at least 2035; and positive efficacy comparison data presented at AUA showing its Nai+BCG therapy outperforming Nadofaragene and TAR-200 in complete response rates.

Despite these fundamentally positive developments, elevated trading volume suggests profit-taking pressure as multiple catalysts were simultaneously digested by the market. The pattern is consistent with a classic post-catalyst retracement following rapid appreciation.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)